Delcath Systems Inc (DCTH) is a Healthcare · Medical Devices company listed on NASDAQ. Price $16.11 (-0.86%), Market cap $0.40B, P/E ratio 1146.00, 52-week low–high $8.19 ~ $18.10.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name fo
Financial statements, price targets, institutional (13F) holdings and related news for Delcath Systems Inc are updated in real time on BlackAll Trade.
Delcath Systems Inc trades at $16.11 (-0.86%). Real-time quotes and charts are available on BlackAll Trade.
Delcath Systems Inc has a market cap of about $0.40B. Its P/E ratio is 1146.00.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEP